Eun Yang
Stock Analyst at Jefferies
(0.53)
# 4,211
Out of 5,122 analysts
32
Total ratings
35.29%
Success rate
-23.05%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GBIO Generation Bio Co. | Downgrades: Hold | $11 → $5 | $5.70 | -12.28% | 1 | Dec 16, 2025 | |
| RIGL Rigel Pharmaceuticals | Upgrades: Buy | $23 → $42 | $36.20 | +16.02% | 1 | Nov 5, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $478.27 | -9.67% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $4.72 | +69.49% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.63 | +139.62% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $78.18 | -57.79% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.11 | +2,422.52% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $27.60 | -2.17% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.82 | +284.62% | 1 | Feb 10, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $3.81 | +556.17% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105,000 → $15,000 | $2.40 | +624,900.00% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.49 | +1,577.85% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $25.48 | +37.36% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $338.59 | -35.02% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $176.76 | +75.38% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $143.28 | -44.17% | 3 | Jul 11, 2017 |
Generation Bio Co.
Dec 16, 2025
Downgrades: Hold
Price Target: $11 → $5
Current: $5.70
Upside: -12.28%
Rigel Pharmaceuticals
Nov 5, 2025
Upgrades: Buy
Price Target: $23 → $42
Current: $36.20
Upside: +16.02%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $478.27
Upside: -9.67%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $4.72
Upside: +69.49%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.63
Upside: +139.62%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $78.18
Upside: -57.79%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.11
Upside: +2,422.52%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $27.60
Upside: -2.17%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.82
Upside: +284.62%
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $3.81
Upside: +556.17%
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $2.40
Upside: +624,900.00%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.49
Upside: +1,577.85%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $25.48
Upside: +37.36%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $338.59
Upside: -35.02%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $176.76
Upside: +75.38%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $143.28
Upside: -44.17%